Denmark rejects reimbursement for migraine drug Aimovig
The price of Novartis and Amgen’s CGRP migraine product does not match its therapeutic value, a Danish authority says.
by albert rønning-andersson, translated by daniel pedersen
Danish patients will continue to bear the full cost if they pursue treatment with preventive migraine drug Aimovig (erenumab), which is marketed by Novartis and Amgen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Denmark recommends Lundbeck migraine treatment
For subscribers
.jpg&w=384&q=75)
